Hematopoietic Stem Cell Transplantation for Infants with High-Risk KMT2A Gene–Rearranged Acute Lymphoblastic Leukemia

43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.